Can I Take Melatonin with Finasteride?

Why This Combination Comes Up So Often

Finasteride is one of only two FDA-approved oral drugs for androgenetic alopecia, prescribed to millions of men each year. Melatonin is the most widely used over-the-counter sleep supplement in the United States, taken by roughly 21% of adults with sleep difficulties according to a 2023 CDC analysis. The overlap in user demographics is large: men in their 20s through 50s managing hair loss who also want help falling asleep.

The Core Question

Because both compounds pass through the liver's cytochrome P450 system, patients reasonably ask whether one drug could amplify or blunt the other. The short answer is that their primary metabolic routes diverge enough that a dangerous interaction is not expected.

What the Interaction Databases Say

Neither the Natural Medicines Comprehensive Database nor the Mayo Clinic drug interaction checker flags a direct contraindication between finasteride and melatonin. The interaction is categorized as theoretical or non-significant in most clinical decision-support tools. That does not mean zero overlap exists. It means the overlap is unlikely to produce harm at typical doses.

How Finasteride Is Metabolized

Finasteride is a 4-azasteroid compound that selectively inhibits type II 5-alpha reductase, the enzyme that converts testosterone to dihydrotestosterone (DHT). Understanding its metabolic pathway clarifies where a supplement might interfere.

CYP3A4: The Dominant Route

Finasteride undergoes extensive hepatic metabolism primarily via CYP3A4. The drug is converted to inactive metabolites that are excreted in both urine and feces. Its oral bioavailability is approximately 80%, and it has a terminal half-life of 5 to 6 hours in men aged 18 to 60 (extending to roughly 8 hours in men over 70).

Minor Pathways

CYP1A2 and CYP2C9 contribute to finasteride metabolism at a secondary level. Under normal conditions, these pathways handle a small fraction of total clearance. They become more relevant only if CYP3A4 is heavily inhibited by another drug, such as ketoconazole or ritonavir.

Because melatonin does not meaningfully inhibit or induce CYP3A4, it is unlikely to alter finasteride blood levels in any clinically detectable way.

How Melatonin Is Metabolized

Melatonin is an endogenous neurohormone produced by the pineal gland. Exogenous melatonin supplements undergo rapid first-pass hepatic metabolism, resulting in oral bioavailability of roughly 15%.

CYP1A2: The Rate-Limiting Enzyme

The principal enzyme responsible for melatonin's 6-hydroxylation is CYP1A2. This is not the primary enzyme for finasteride. The distinction matters: drugs that share the same dominant CYP isoform compete for binding, potentially raising plasma levels of one or both compounds. Since finasteride relies on CYP3A4 and melatonin relies on CYP1A2, the competitive risk is minimal.

Drugs That Do Alter Melatonin Levels

For context, fluvoxamine (a potent CYP1A2 inhibitor) can increase melatonin area-under-the-curve by more than 17-fold. Caffeine, another CYP1A2 substrate, can modestly raise melatonin levels when consumed in the evening. Finasteride has no comparable effect on CYP1A2.

Pharmacodynamic Considerations

Even when two drugs don't compete for the same metabolic enzyme, they can still interact at the receptor or physiological level. This is called a pharmacodynamic interaction.

Melatonin and Glucose Tolerance

Melatonin receptors (MT1 and MT2) are expressed on pancreatic beta cells. A 2020 systematic review in Diabetes Care confirmed that the MTNR1B risk variant rs10830963 is associated with impaired fasting glucose. Exogenous melatonin taken at doses above 3 mg can transiently reduce glucose tolerance in some individuals, particularly those carrying this variant.

Finasteride does not directly affect glucose metabolism. A 2019 observational study in the Journal of Clinical Endocrinology & Metabolism found that 5-alpha reductase inhibitors may modestly alter insulin sensitivity through changes in steroid metabolism, but the magnitude was small and variable.

What This Means in Practice

If you are prediabetic or have type 2 diabetes, the additive glucose effect of high-dose melatonin plus the subtle metabolic shifts from finasteride could warrant monitoring fasting glucose. For most healthy men, this is not a concern at melatonin doses of 0.5 to 3 mg.

Sedation and CNS Effects

Finasteride has been associated with neuropsychiatric symptoms in a subset of users, including depressive mood, brain fog, and sleep disturbance. A 2019 analysis published in JAMA Dermatology reviewed FDA Adverse Event Reporting System data and confirmed reports of insomnia and somnolence with finasteride, though causality remains debated.

Melatonin promotes sleep onset. If finasteride is contributing to daytime fatigue or sleep architecture disruption, adding melatonin could either help (by improving sleep quality) or, rarely, compound next-day grogginess. Monitoring how you feel in the first two weeks is the practical solution.

Dose-Separation Strategy

No regulatory agency mandates a specific separation window between these two drugs. The recommendation to separate by 1 to 2 hours is a conservative, pharmacology-informed strategy rather than a hard clinical rule.

Why Separation Helps

Staggering oral drugs reduces peak competition for shared minor enzymes (in this case, CYP1A2). It also lets you attribute any side effect, such as dizziness or stomach upset, to the correct drug.

Suggested Timing

Finasteride can be taken at any time of day. Most men take it in the morning with or without food. Melatonin is taken 30 to 60 minutes before desired sleep onset. This natural dosing pattern already creates a separation of 12 or more hours for most users. If you prefer taking finasteride at night, simply take it at dinner and melatonin at bedtime.

Melatonin and Hair Loss: An Emerging Signal

An unexpected overlap between these two compounds is that melatonin itself may have hair-growth properties. A 2012 randomized, double-blind trial published in the International Journal of Trichology evaluated a topical melatonin solution in women with androgenetic alopecia and found significant increases in anagen hair count at 3 and 6 months versus placebo.

Mechanism of Melatonin in Hair Follicles

Melatonin receptors are expressed in human hair follicle cells. In vitro studies have demonstrated that melatonin extends the anagen (growth) phase of the hair cycle and acts as an antioxidant within the follicular microenvironment. A 2018 review in the Journal of Pineal Research summarized that melatonin's follicular effects are independent of its sleep-promoting action and appear to operate through MT1 and MT2 receptor signaling in dermal papilla cells.

Does Oral Melatonin Reach the Follicle?

Topical melatonin delivers higher local concentrations to the scalp than oral dosing. Whether the plasma levels achieved by a 1 to 5 mg oral dose provide meaningful follicular benefit is unknown. No trial has tested oral melatonin as a hair loss treatment. Patients should not take melatonin orally expecting it to augment finasteride's hair-growth effect.

Monitoring Recommendations

For most men combining finasteride 1 mg (for hair loss) with melatonin 0.5 to 5 mg, no special lab monitoring is required beyond what finasteride alone warrants.

Baseline and Ongoing Checks

Finasteride lowers PSA by approximately 50% within 6 months, which must be accounted for in prostate cancer screening. If your physician checks PSA, inform them you are on finasteride so the value can be doubled for accurate interpretation. Melatonin does not affect PSA.

When to Add Glucose Monitoring

Consider checking fasting glucose or HbA1c if you:

• Take melatonin at doses above 5 mg nightly
• Have prediabetes or a family history of type 2 diabetes
• Notice increased thirst, frequent urination, or unexplained weight change after starting the combination

Mood and Sleep Diary

Because both drugs can independently influence mood and sleep architecture, keeping a brief daily log for the first 30 days is practical. Record sleep onset latency, number of awakenings, morning alertness, and any mood changes. This data helps your prescriber make informed adjustments.

What to Do If You Are Already Taking Both

If you have been combining melatonin and finasteride without problems, there is no reason to stop. The absence of a documented pharmacokinetic interaction, combined with decades of post-marketing experience with both drugs, supports continued use.

Red Flags That Warrant a Prescriber Visit

Stop melatonin and contact your physician if you experience:

• Persistent next-day drowsiness that impairs driving or work
• New-onset depressive symptoms, particularly if they appeared after adding melatonin to finasteride
• Breast tenderness or gynecomastia (a known finasteride side effect occurring in roughly 1.8% of men at 1 mg/day), as melatonin may modulate prolactin in some individuals

Adjusting Melatonin Dose

Clinical evidence supports starting melatonin at the lowest effective dose. A 2013 meta-analysis in PLOS ONE (N = 1,683 across 19 trials) found that melatonin reduced sleep onset latency by a weighted mean of 7.06 minutes and increased total sleep time by 8.25 minutes. Higher doses did not proportionally improve outcomes. Beginning at 0.5 mg and titrating upward only if needed minimizes any theoretical pharmacodynamic overlap.

Special Populations

Men Over 65

Finasteride clearance slows with age. The terminal half-life extends from about 6 hours to 8 hours. Melatonin metabolism also declines with reduced CYP1A2 activity in older adults. While neither change is dramatic, additive sedation risk increases. Start melatonin at 0.5 mg in this group.

Men on CYP3A4 Inhibitors

If you take a strong CYP3A4 inhibitor (ketoconazole, itraconazole, clarithromycin, or ritonavir), finasteride clearance may decrease and plasma levels may rise. This does not directly involve melatonin, but a higher finasteride exposure could amplify side effects that might be mistakenly attributed to the supplement. Inform your prescriber of all concurrent medications.

Men With Hepatic Impairment

Both drugs are extensively liver-metabolized. In patients with significant hepatic impairment (Child-Pugh B or C), clearance of both compounds may be reduced. Finasteride's label does not include formal hepatic dosing adjustments, but caution is warranted. Melatonin levels can rise substantially in cirrhosis. A physician should supervise this combination in anyone with known liver disease.

The Bottom Line on Safety

The pharmacokinetic evidence is reassuring. Finasteride and melatonin use different primary CYP450 pathways (CYP3A4 versus CYP1A2), and no published case report or pharmacovigilance signal describes a clinically significant interaction. The pharmacodynamic overlap is limited to minor, dose-dependent effects on glucose tolerance and a theoretical additive sedation profile.

For a healthy man taking finasteride 1 mg daily for hair loss and melatonin 0.5 to 3 mg at bedtime, standard monitoring (annual PSA adjusted for the finasteride effect, periodic liver function if clinically indicated) is sufficient. Start melatonin at 0.5 mg, take finasteride in the morning, and track sleep quality for the first month.